About Octave Bioscience
Octave Bioscience is a private company based in Menlo Park, California. It has reported $105,840,424 raised in five offerings on Form D since September 2017. Its chief executive is Doug Biehn.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 7, 2025 | Mar 24, 2025 | $31,840,355of $53.6M target | 20 | $1.5M | EquityRule 506(b) | Form D ↗ |
| Sep 26, 2023 | Nov 24, 2023 | $6,999,999fully sold | 2 | $3.4M | EquityRule 506(b) | Form D ↗ |
| Jan 4, 2023 | Nov 24, 2023 | $32,500,070of $37.5M target | 20 | $1.6M | EquityRule 506(b) | Form D ↗ |
| Oct 29, 2020 | Jan 7, 2021 | $32,000,000fully sold | 14 | $2.2M | EquityRule 506(b) | Form D ↗ |
| Nov 26, 2014 | Sep 13, 2017 | $2,500,000fully sold | 7 | $357K | EquityRule 506(b) | Form D ↗ |
| Total, five offerings | $105,840,424 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Octave Bioscience's Form D filed Mar 24, 2025.
AI
A. Grant Heidrich III
Director
GS
George Scangos
Director
WH
William Hagstrom
Director
MK
Marcel Konrad
Executive officer
BB
Brook Byers
Director
DB
Doug Biehn
Chief Executive Officer and director
LC
Lucy Coassin
Director
MP
Michael Pellini
Director
Earlier filings also listed Melinda Thomas (executive officer, last listed Nov 2023), Andrea Jackson (director, last listed Nov 2023) and Mark Weeks (executive officer, last listed Jan 2021).